Consented patients
2,800 → 2,940
Baseline → modeled
PSP Connect
PSP Connect Platform
Connect the workflow. Make the gaps visible.
Explore how CareSync PSP Connect brings patient services, care-team coordination and program operations together. Trace each capability from a practical program gap to a measurable process—and a transparent planning scenario.
From program gaps to connected services.
Select a workflow to explore the experience, who uses it and what to measure. Product screens use demonstration data; capabilities support your teams, not autonomous clinical decisions.
Enrollment & consent
Program gap
Incomplete forms and disconnected intake make it hard to see where eligible patients drop out.
Features & services
Digital enrollment, eligibility review, consent forms and patient profiles connect the intake journey. Program teams coordinate outstanding steps and handoffs.
What to measure
Eligible-to-consented conversion, consent completeness and enrollment administration time.
Evidence connection
Marshall’s care-coach study supports measuring initiation and contact completion; it does not establish a CareSync enrollment uplift.
Product preview · Demonstration data
Published PSP research
Evidence for better program decisions.
A clearer view of medication coverage, continuity and cost. These external studies help define the questions PSP Connect can help your team measure.
External observational findings—not measured CareSync results, local forecasts or guaranteed improvements. Related endpoints must not be added together.
- Mean medication coverage (PDC)
- 64.8%
Versus 50.1% without PSP participation. PDC measures days covered—not the share of adherent patients.
Brixner · 2019 - Discontinuation at 12 months
- 51.4%
Versus 65.9% without PSP participation; a lower discontinuation rate in the same Brixner cohort.
Brixner · 2019 - Lower medical costs
- 29.2%
Excludes biologic / targeted drugs. Total costs including these drugs were not significantly lower (p=0.056).
Brixner · 2019 - Median time to discontinuation
- 673days
Versus 574 days without PSP participation. Israeli cohort of 1,520 adalimumab initiators; not a universal persistence target.
Srulovici · 2018
Brixner et al., 2019 · Sponsor-funded US adalimumab study · 2,268 matched patients. Srulovici et al., 2018 · Sponsor-funded retrospective Israeli cohort. Associations do not establish causation; local applicability requires validation.
Explore the supplied research reportIllustrative estimates · Not measured outcomes
Test how closing gaps changes the program.
These conservative, central and stretch scenarios use the existing PSP estimator. They are assumptions, not published effect sizes. Gains apply only to the digitally supported fraction, and cohort stages compound.
Activated patients
2,100 → 2,370
Baseline → modeled
Continuing patients
1,365 → 1,627
Baseline → modeled
Completed contacts
7,560 → 9,526
Baseline → modeled
View baseline and scenario assumptions
- Eligibility %
- 80
- Consent %
- 70
- Activation %
- 75
- Persistence %
- 65
- Contacts per patient
- 6
- Contact completion %
- 60
- Enrollment minutes
- 30
- Contact minutes
- 15
- Refill gap %
- 20
- Refill support minutes
- 15
- Consent gain, pp
- 5
- Activation gain, pp
- 8
- Discontinuation gap recovery %
- 15
- Contact gain, pp
- 10
- Refill gap recovery %
- 25
- Administration reduction %
- 20
- Data completeness gain, pp
- 10
- Safety ownership gain, pp
- 10
Long-term operational economics
No CareSync prices are assumed. Enter your actual local costs to calculate cash impact. Leaving costs at zero does not demonstrate free deployment or a savings claim.
Net annual team hours
-40
Gross administration hours avoided
542
Hours avoided are not automatically cash savings. Net hours deduct the workload of added patients, contacts and refill support. Positive hours use your cash-realization rate; extra workload is charged at the full hourly rate.
Constant annual cohort and assumptions; setup is deducted once, recurring and incremental costs every year. Undiscounted, with no growth, inflation or automatic compounding of savings. Negative results remain visible. Clinical-study medical costs are excluded.
Open the full PSP estimatorThe services behind a well-scoped launch.
Platform configuration is one part of delivery. Align the service model and acceptance criteria with patient services, operations, clinical, IT and pharmacovigilance stakeholders.
- 1
Journey & KPI design
Map intake, patient services and handoffs. Agree cohort definitions, baseline measurements and review cadence.
- 2
Brand & workflow configuration
Configure branding, languages, roles, consent forms, follow-up plans and reporting around the agreed therapy and program.
- 3
Integration planning
Define interfaces, identity, communications and data flows with IT. Availability and implementation effort depend on the systems and agreed scope.
- 4
Validation & team enablement
Review permissions, workflow acceptance and safety transfer responsibilities; train teams before launch.
- 5
Ongoing operational review
Review adoption, workload and data quality. Refine the configured experience against agreed measures and support terms.
CareSync PSP Connect · Featured case study
From program to platform
How integrated digital PSPs improve outcomes, adherence and value
Explore the published evidence behind integrated patient support, the people and workflows connected by PSP Connect, and an illustrative Saudi Arabia scenario for evaluating potential value.
- Global evidence
- Connected patient journeys
- Illustrative KSA scenario
Published findings come from external studies, not measured CareSync outcomes. The Saudi scenario uses unvalidated assumptions; it is not an investment forecast or a guarantee of ROI.
Read the case studyPDF · 7 pages · English · September 2026
Your personalized demo
Your care. Your brand. One platform.
See how CareSync brings your patients and teams together in a branded experience.
- Live demo
- Solution mapping
- Commercial proposal
Prefer to talk first?
Chat on WhatsApp